Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $183K | $206K | $213K | $467K | $1.24M | $3.51M | $3.31M | $6.59M | $3.55M |
| Revenue growth | — | — | 12.5% | 3.5% | 118.9% | 166.0% | 183.0% | -5.8% | 99.1% | -46.2% |
| Operating income | -$8.49M | -$11.5M | -$148M | -$22.5M | -$28.9M | -$39.5M | -$19.8M | -$14.6M | -$11.1M | -$12.9M |
| Operating margin | — | -6271.1% | -71930.1% | -10567.3% | -6188.2% | -3179.3% | -563.3% | -440.4% | -168.7% | -363.5% |
| Net income | -$2.46M | -$11.0M | -$148M | -$21.4M | -$28.7M | -$41.9M | -$29.9M | -$8.24M | -$10.7M | -$12.2M |
| Net margin | — | -5999.1% | -71826.3% | -10050.9% | -6149.7% | -3372.7% | -851.9% | -248.8% | -162.8% | -343.0% |
| EPS (diluted) | -$0.72 | -$1.16 | -$7.75 | -$0.47 | -$0.61 | -$5.47 | -$3.58 | -$0.94 | -$1.19 | -$0.79 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.51M | -$8.44M | -$14.5M | -$18.3M | -$20.0M | -$27.3M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
| Capital expenditures | — | $0.00 | $148K | $375K | — | — | — | — | — | — |
| Free cash flow | — | -$8.44M | -$14.6M | -$18.7M | — | — | — | — | — | — |
| Share buybacks | $0.00 | $310K | $71.7K | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $5.13M | $61.7M | $43.9M | $21.4M | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Total assets | $7.92M | $5.18M | $62.1M | $46.4M | $45.6M | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Total liabilities | $1.74M | $1.52M | $2.80M | $2.27M | $18.3M | $24.1M | $14.8M | $3.07M | $3.46M | $2.27M |
| Shareholders' equity | $6.18M | $3.66M | $59.3M | $44.1M | $27.3M | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Retained earnings | -$146M | -$157M | -$306M | -$328M | -$356M | -$398M | -$428M | -$436M | -$447M | -$459M |
| Shares (wtd avg diluted) | 7.42M | 9.45M | 19.1M | 45.6M | 47.0M | 7.65M | 8.35M | 8.81M | 8.98M | 15.3M |
Every figure is extracted from Marker Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.